Objective
Thalassemia syndromes prevail in Mediterranean and South East Asia populations. In Greece and Thailand thalassemias have a high prevalence, creating a major public health problem, with severe socioeconomic impact. of the two basic clinical phenotypes of Thalassemias, (major and Intermedia) thalassemia intermedia (Thal.I) is not well-defined and studied.
The main objective of this project is to establish precise criteria for characterization of Thal.I at the molecular level. This will be achieved by analysis of the a and beta gene cluster defects in a large number of thalassemic patients with mild clinical manifestations. Two populations, known for the high prevalence and the extreme heterogeneity (genetic, hematological, and clinical) of a, B, 6B thalassemias, will be studied. For molecular studies advanced DNA techniques will be applied and new techniques will be introduced when necessary. One of these will be the selection of fetal cells in maternal blood, for DNA analysis and antenatal diagnosis. In each population, the main molecular defects related to Thal.I will be evaluated in respect to the hematological, biochemical and biosynthetic expression of the heterozygous, homozygous or double heterozygous State, utilizing sensitive techniques available in the three collaborating units. The establishment of a precise relation of the molecular defect to hematological and other laboratory findings, will facilitate assessment of the clinical severity of thalassemia intermedia; such assessment will enable clinicians to provide the appropriate treatment and prevention. In addition the prospective molecular, hematological and clinical studies of thalassemic patients with mild clinical manifestations, is expected to clarify the pathogenetic mechanism ameliorating the clinical manifestations in patients with Thal.I. The work is expected to complete existing studies on the characterization and distribution of mutations of thalassemia syndromes in various populations, evaluate new techniques for diagnosis and prevention, and expand therapeutic trials with hydroxyurea to ameliorate the clinical symptoms in selected patients with beta-th/Hbe, beta-th/Hbs diseases and other severe B Thal.I patients.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences health sciences public health
- natural sciences biological sciences genetics DNA
- natural sciences biological sciences genetics mutation
You need to log in or register to use this function
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Data not available
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Data not available
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
10561 ATHENS
Greece
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.